Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 milligram dose of the drug,

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight loss treatment. It has shown remarkable results in reducing body weight, making it a popular choice for those struggling with obesity or overweight.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially approved for managing type 2 diabetes. While there is currently limited data on its risks and benefits for those with type 1 diabetes,

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your overall well-being.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its blockbuster obesity drug Wegovy, helped overweight patients lower their weight by 20.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.